Prioritised health outcome (n = 19)a | Type of proposed change | Total proposed changes | Total observed changes | ||||
---|---|---|---|---|---|---|---|
Stop | Dose increase | Dose decrease | Switch | Unknown | |||
Remaining alive (n = 6) | 5 Desloratadine Mebeverineb Omeprazole Tamsulosin Tiotropium | 1 Levothyroxine | 4 Domperidone Macrogol (2×)c Simvastatin | 1 Temazepam to Melatonin | 0 | 11 | 3 stopped Mebeverineb Macrogol (2×)c |
Maintaining independence (n= 7) | 7 Alendronic acidb Atorvastatin Hydrochlorothiazide Omeprazole Propranololb Simvastatin Tamsulosin | 1 Salbutamol | 2 Acetylsalicylic acid Allopurinolc | 0 | 0 | 10 | 3 stopped Alendronic acidb Propranololb Allopurinolc |
Reducing pain (n= 1) | 1 Citolapram | 0 | 0 | 0 | 0 | 1 | 0 |
Reducing other symptoms (n= 5) | 8 Alendronic acidb Atorvastatin Calcium/vitamin Db Ferrous sulphateb Gliclazideb Simvastatin (3×)b | 0 | 0 | 2 Morphine to Buprenorphine Acenocoumarol to Acetyl-salicylic acidc | 1 Morphinec | 11 | 7 stopped Alendronic acidb Calcium/vitamin Db Ferrous sulphateb Gliclazideb Simvastatin (2×)b Acenocoumarolc 1 dose decrease Morphinec |
Total | 21a | 2 | 6 | 3 | 1 | 33a | 14 |
↵a One patient gave the highest priority to both maintaining independence and reducing other symptoms, and is not included (proposed but not observed stop of betahistine).
↵b Observed change in agreement with the proposed change.
↵c Observed change adapted from the proposed change, or agreement unknown.